Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers

seekingalpha2022-02-15

Moderna closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

186

Report

Comment（12）

Charis4455
·2022-02-15
Oh no :(
Reply
Like
Report
KeN3
·2022-02-15
Boosters are like more than annually now, don't see how the drop comes about
Reply
1
Report
ValuInvestor
·2022-02-15
Aren't we forgetting about yearly boosters?
Reply
2
Report
TaiJin
·2022-02-15
👍👍👍
Reply
1
Report
DonkeyKONG
·2022-02-15
Yikeeees!
Reply
1
Report
Steven Tay
·2022-02-15
Like
Reply
2
Report
koolgal
·2022-02-15
If Covid-19 cases were to decline, perhaps the vaccine stocks will be impacted. However in many parts of the world especially the poorer nations Covid-19 is still prevalent. So for now, Vaccine companies are still in the forefront of our fight against Covid-19.
Reply
8
Report
whereareyou
·2022-02-15
[Drowsy]
Reply
1
Report
Apple888
·2022-02-15
[Surprised]
Reply
5
Report
Yappy
·2022-02-15
Like
Reply
3
Report
LuckyPiggie
·2022-02-15
Ohhhh ....
Reply
2
Report
PBL77
·2022-02-15
Ok
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2211029965?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-15 11:00","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2211029965","market":"us","top_or_hot":-1,"title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","media":"seekingalpha","content":"<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","article_id":"2211029965","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","pubTimestamp":1644894043,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4139":"生物科技","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BNTX":"BioNTech SE","PFE":"辉瑞","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓"},"translate_title":"周一莫德纳股票为何下跌？对疫苗制造商的信心减弱","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1,"MRNA":1,"PFE":1},"content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9095282210,"gmtCreate":1644929653043,"gmtModify":1676533976427,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"htmlText":"Oh no :(","listText":"Oh no :(","text":"Oh no :(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095282210","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095654332,"gmtCreate":1644906414664,"gmtModify":1676533974541,"author":{"id":"4090570965971460","authorId":"4090570965971460","name":"KeN3","avatar":"https://static.tigerbbs.com/ffc770a2d3626a3e029ba2c461aac13d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4090570965971460","authorIdStr":"4090570965971460"},"htmlText":"Boosters are like more than annually now, don't see how the drop comes about","listText":"Boosters are like more than annually now, don't see how the drop comes about","text":"Boosters are like more than annually now, don't see how the drop comes about","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095654332","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095629022,"gmtCreate":1644900780511,"gmtModify":1676533973960,"author":{"id":"4087361572396550","authorId":"4087361572396550","name":"ValuInvestor","avatar":"https://static.tigerbbs.com/5a962911d3cd0763a9f0cb01392cacd9","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087361572396550","authorIdStr":"4087361572396550"},"htmlText":"Aren't we forgetting about yearly boosters?","listText":"Aren't we forgetting about yearly boosters?","text":"Aren't we forgetting about yearly boosters?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095629022","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095667667,"gmtCreate":1644900370245,"gmtModify":1676533973937,"author":{"id":"3585363622677550","authorId":"3585363622677550","name":"TaiJin","avatar":"https://static.tigerbbs.com/24d2d840485600ee9789f516e956a70f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585363622677550","authorIdStr":"3585363622677550"},"htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095667667","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095667802,"gmtCreate":1644900368178,"gmtModify":1676533973929,"author":{"id":"3582724800434376","authorId":"3582724800434376","name":"DonkeyKONG","avatar":"https://static.tigerbbs.com/74b283ac3588c9a89ff23d8719ba98d6","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582724800434376","authorIdStr":"3582724800434376"},"htmlText":"Yikeeees!","listText":"Yikeeees!","text":"Yikeeees!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095667802","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095663881,"gmtCreate":1644898553585,"gmtModify":1676533973743,"author":{"id":"4099285253763630","authorId":"4099285253763630","name":"Steven Tay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4099285253763630","authorIdStr":"4099285253763630"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095663881","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095681895,"gmtCreate":1644895954946,"gmtModify":1676533973517,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":6,"crmLevelSwitch":1,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"htmlText":"If Covid-19 cases were to decline, perhaps the vaccine stocks will be impacted.&nbsp; However in many parts of the world especially the poorer nations Covid-19 is still prevalent. So for&nbsp;now, Vaccine companies are still in the forefront of our fight against Covid-19.&nbsp;","listText":"If Covid-19 cases were to decline, perhaps the vaccine stocks will be impacted.&nbsp; However in many parts of the world especially the poorer nations Covid-19 is still prevalent. So for&nbsp;now, Vaccine companies are still in the forefront of our fight against Covid-19.&nbsp;","text":"If Covid-19 cases were to decline, perhaps the vaccine stocks will be impacted. However in many parts of the world especially the poorer nations Covid-19 is still prevalent. So for now, Vaccine companies are still in the forefront of our fight against Covid-19.","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095681895","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095681007,"gmtCreate":1644895898108,"gmtModify":1676533973515,"author":{"id":"4106958589832490","authorId":"4106958589832490","name":"whereareyou","avatar":"https://static.itradeup.com/news/1e1404e84b34f5746764c809e3ee03f2","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":6,"crmLevelSwitch":0,"idStr":"4106958589832490","authorIdStr":"4106958589832490"},"htmlText":"[Drowsy]&nbsp;","listText":"[Drowsy]&nbsp;","text":"[Drowsy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095681007","repostId":2211029965,"repostType":2,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095683733,"gmtCreate":1644895889540,"gmtModify":1676533973525,"author":{"id":"3552793013435190","authorId":"3552793013435190","name":"Apple888","avatar":"https://static.tigerbbs.com/3cd881eacfe2b6de7045a1744276477c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3552793013435190","authorIdStr":"3552793013435190"},"htmlText":"[Surprised]&nbsp;","listText":"[Surprised]&nbsp;","text":"[Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095683733","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095614899,"gmtCreate":1644894802916,"gmtModify":1676533973146,"author":{"id":"3572077804076143","authorId":"3572077804076143","name":"Yappy","avatar":"https://static.tigerbbs.com/ab4d89913ade03f15c782b99132ba22f","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3572077804076143","authorIdStr":"3572077804076143"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095614899","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095615553,"gmtCreate":1644894691372,"gmtModify":1676533973130,"author":{"id":"4107063207857540","authorId":"4107063207857540","name":"LuckyPiggie","avatar":"https://community-static.tradeup.com/news/33330ac1fe6d6c956e10045c870d6f46","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":6,"crmLevelSwitch":1,"idStr":"4107063207857540","authorIdStr":"4107063207857540"},"htmlText":"Ohhhh ....&nbsp;","listText":"Ohhhh ....&nbsp;","text":"Ohhhh ....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095615553","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095615829,"gmtCreate":1644894661040,"gmtModify":1676533973122,"author":{"id":"4087190594214920","authorId":"4087190594214920","name":"PBL77","avatar":"https://static.tigerbbs.com/8ef4f93ba3e261ac276aef28c4467365","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4087190594214920","authorIdStr":"4087190594214920"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095615829","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://ttm.financial/m/news/2211029965?lang=&edition=fundamental","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","PFE":"辉瑞","BNTX":"BioNTech SE","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":186,"commentSize":12,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}